WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops novel
anticancer therapeutics using its antibody-drug conjugate (ADC)
technology, today announced that the following presentations by Company
management at upcoming investor conferences will be webcast:
-
Bank of America Merrill Lynch 2014 Health Care Conference
5:00pm
PT (8:00pm ET), May 14 in Las Vegas, NV
-
Jefferies 2014 Global Healthcare Conference
10:00am ET,
June 4 in New York, NY
The webcasts will be accessible live through the "Investor Information"
section of the Company's website, www.immunogen.com;
a replay will be available for approximately a week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen
cell-killing agent specifically to cancer cells; the Company has also
developed antibodies with anticancer activity of their own. The first
product with ImmunoGen's ADC technology is Roche's Kadcyla®.
ImmunoGen has three wholly owned product candidates in clinical testing
with additional compounds in clinical testing through the Company's
partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More
information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of
the Roche Group.
Contacts
For Investors:
ImmunoGen, Inc.
Carol Hausner,
781-895-0600
info@immunogen.com
or
For
Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
Source: ImmunoGen, Inc.
News Provided by Acquire Media